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INTRODUCTION
With an estimated 132,700 new diagnoses and 49,700 deaths in 2015, colorectal cancer (CRC) remains one of the most common cancers in the US 1 . Family and twin studies estimate 20 -30% of CRC is due to heritable factors 2-4 . Great strides have been made in understanding genetic factors that underlie CRC risk 5 . However, known genetic factors only explain about one third of familial risk of CRC 3 .
Ribosomal protein S20 (RPS20, [OMIM: 603682]) is a highly-conserved component of the 40S small ribosomal subunit that also functions in 18S rRNA processing 6 . Two studies have reported a link between truncating germline variants in RPS20 and CRC. One frameshift variant (c.147dupA, p.Val50SerfsTer23) was reported to segregate with CRC in a large Finnish family 7 . A second frameshift variant (c.181_182delTT, p.Leu61GlufsTer11) as well as a predicted deleterious missense variant (c.160G>C, p.Val54Leu) were identified in a single CRC case each during whole exome sequencing of 863 CRC cases; no rare missense or truncating variants were identified in 1604 controls 8 .
Here we report a novel germline splice donor variant in RPS20 (c.177+1G>A) identified in a CRC case from a case-control screen. This variant segregates with CRC and polyposis in additional family members.
METHODS

Editorial Policies and Ethical Considerations
Research was approved by the University of Utah Institutional Review Board. Individuals provided informed consent for genetic research under University of Utah protocols prior to collection of DNA, RNA, and/or FFPE tissue samples as well as medical record information.
Case-Control Sequencing
Detailed methods for the case-control screen are provided in the Supplemental Methods. Briefly, DNA libraries were prepared from 746 CRC cases and 1,525 cancer-free controls using the Ovation Ultralow 
Statistics and Bioinformatics
Gene-disease association tests in the case-control cohort were performed using PERCH 10 and VAAST 11 . A significance level of P = 2.5 x 10 -4 was set based on Bonferroni correction of P = 0.05 12 . MaxEntScan was used to predict alterations in splicing for RPS20 13 . RVsharing software was used to calculate the probability of the observed transmission of RPS20 c.177+1G>A in the pedigree 14 .
RPS20 Genotyping RPS20 variant positions correspond to RefSeq NM_001023.3. DNA was extracted from whole blood (proband) using Qiagen AutoPure LS (Qiagen #2016391) or from saliva (additional pedigree members) using Oragene•DISCOVER (DNA Genotek #OGR-500). The variant-containing region was PCR amplified and Sanger sequenced ( Supplemental Table S1 ).
RPS20 Reverse Transcription-PCR (RT-PCR)
Total RNA for the proband was extracted from whole blood using the PAXgene Blood RNA system (Qiagen #762164, #762165). Total RNA for the two controls was extracted from whole blood using a Qiagen miRNAeasy Mini Kit (Qiagen #217004). cDNA was produced using SuperScript IV VILO (Invitrogen #11756050), then PCR amplified and analyzed by gel electrophoresis ( Supplemental Table S1 ).
Three bands present for the proband (370bp, 444bp, 591bp) were cut from the agarose gel and incubated at 4 o C overnight in 10mM Tris, 1mM EDTA, pH 8.0. A 5 µL aliquot of the resulting solution was used as a template in a second PCR reaction. These PCR products were treated with ExoSAP-IT (Affymetrix #78200), then analyzed by Sanger sequencing ( Supplemental Table S1 ).
Loss-of-Heterozygosity Analysis
DNA from individual II-3 ( Figure 1 ) was extracted from normal colon and adenocarcinoma FFPE tissue.
The RPS20 variant was PCR amplified ( Supplemental Table S1 ), and PCR bands were extracted using a QIAquick Gel Extraction kit (Qiagen #28704). DNA was treated with ExoSAP-IT prior to Sanger sequencing. Chromatographs from normal and tumor samples were compared by visual inspection.
RESULTS
Germline DNA from CRC cases and controls was sequenced for 59 published (including RPS20) and 137 candidate cancer susceptibility genes (Supplemental Table S2 ). None of the 196 genes have a significant association with CRC after correction for multiple testing. However, a single rare variant in the canonical splice donor dinucleotide of RPS20 intron 3 was identified in 1/746 CRC case and 0/1525 controls.
Notably, the two previously reported RPS20 variants are also truncating variants located near the junction of exons 3 and 4 ( Figure 1A) . Predicted loss-of-function variants in RPS20 are rare, with only twelve carriers observed in the gnomAD non-cancer database ( Supplemental Table S3 ) 15 . The G>A transition in the conserved splice donor site is predicted to affect mRNA splicing. RT-PCR was targeted to c.177+1G>A for the proband and for two controls with CRC syndromes (Lynch syndrome and familial adenomatous polyposis (FAP)) unrelated to RPS20. RT-PCR revealed three splice products in the proband's mRNA and a single splice product in the two controls ( Figure 1B-E) . The splice products correspond to wild-type RPS20 ( Figure 1D ), exon 3 skipping (r.104_177; p.Val35AspfsTer13, Figure 1E ), and partial inclusion of intron 3 due to activation of a cryptic donor (r.177_178ins177+1_177+147; p.Thr60ValfsTer3, Figure 1C ). The sequence of the intron 3 cryptic splice donor site, CTAgtaagt, is similar to the canonical human splice donor sequence (C/A)AGgt(a/g)agt 16 . It is predicted to be slightly weaker than the wild-type donor site for exon 3 (MaxEntScan scores -WT donor: 9.06; cryptic donor: 8.78), and is exclusively detected in the proband ( Figure 1B) .
The proband's pedigree shows CRC in three of four siblings, the earliest at age 38 ( Figure 2) . Sanger sequencing revealed the c.177+1G>A variant's presence in two siblings with CRC (II-1 and II-3) and one sibling with polyposis (II-4; Figure 2 and Table 1 ). The proband's mother (I-2) is negative for the variant, suggesting it was inherited from the father (I-1), who had CRC at age 58.
CRC tumor and normal tissue was available for individual II-3. There is no evidence of loss-ofheterozygosity comparing tumor and germline DNA, consistent with a previous report on tumors from RPS20 c.147dupA carriers 7 (Supplemental Figure S1 ).
DISCUSSION
This work provides supporting evidence for an association between truncating RPS20 variants and CRC.
Mean age of first CRC diagnosis in this family is 53 years (50 years excluding I-1 whose RPS20 status is unconfirmed), which is similar to the mean age of 52.3 years reported in the pedigree from Finland 7 .
Unlike the Finnish RPS20 family, which was ascertained as having hereditary nonpolyposis colorectal cancer 7 , two carriers in our family had ≥10 polyps (Table 1) . A variable polyp phenotype, including individuals with no polyps, is observed in polyposis syndromes such as attenuated FAP (AFAP) and polymerase proofreading associated polyposis (PPAP) 17, 18 . Identification of additional affected families is required to better define the polyposis and cancer phenotype associated with pathogenic RPS20 variants.
Nieminen et al. proposed haploinsufficiency as the likely mechanism of carcinogenesis for RPS20 7 .
However, a dominant negative mechanism was not ruled out. Nonsense mediated decay (NMD) is not predicted to occur if the premature termination codon (PTC) occurs in the last exon or within the last 50 bp of the penultimate exon 19, 20 . Notably, all reported truncating RPS20 variants linked to CRC are near the exon 3 / 4 boundary, and are predicted to introduce PTCs within the last exon. If translated, all the respective proteins would contain an intact exon 2. Three of the proteins would have the same 10 amino acid C-terminal sequence (Supplemental Figure S2) , with the final four amino acids conforming to the Class I PDZ ligand consensus sequence X[T/S]XΦ, where Φ is a hydrophobic residue and X is any amino acid 21 . Additional families would help elucidate the association between variant type/location and CRC predisposition.
This study is limited by small family size and the young age of the lower generation compared to the median age-of-onset of CRC. Because of this, the association between RPS20 c.177+1G>A and CRC does not reach statistical significance in the family (RVsharing pvalue 0.1429). The case-control analysis of RPS20 also does not show a significant association (PERCH pvalue 0.076; VAAST pvalue 0.0461). Despite these limitations, given the rarity of predicted loss-of-function RPS20 variants in the population 15 , it is important that our results are evaluated in conjunction with existing and emerging data. Future studies should pay particular attention to PTCs that would escape NMD, encode proteins with exons 1-3 mostly intact, and perhaps include a +1 frameshift peptide from exon 4. 
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